Skip to main content
. 2021 Mar;10(3):852–860. doi: 10.21037/gs-20-871

Figure 1.

Figure 1

Overall survival based on the clinical benefit of lenvatinib. The study participants with or without a clinical benefit of lenvatinib (stable disease or partial response) had a median overall survival of 7.6 [95% confidence interval (CI): 2.3–10.3] and 2.8 [95% CI: 1.1–4.7] months, respectively (P=0.042).